Dr. Kalos was Executive Vice President and Head of Research and Development at ArsenalBio. He also served as Vice President, Immunooncology and Oncology Cell Therapies, at Janssen, the Pharmaceutical Companies of Johnson and Johnson, and chief scientific officer at Eli Lilly & Company. Dr. Michael Kalos is a renowned expert in cancer immunotherapy and cell-based therapies. He has contributed significantly to the development of cancer vaccines and adoptive T cell therapies.